Levetiracetam: A novel antiepileptic drug
Levetiracetam: A novel antiepileptic drug
复制标题
DOI：
10.1592/phco.21.17.1375.34432
复制
发表时间：
2001-11-01
期刊：
影响因子：
4.1
通讯作者：
Hovinga, CA
中科院分区：
文献类型：
--
作者：
Hovinga, CA
左乙拉西坦是一种新的抗癫痫药物，在结构和机制上不同于其他市场上销售的抗癫痫药物。无论是作为辅助治疗还是作为单一治疗，它都能有效地减少癫痫患者的部分发作。左乙拉西坦对癫痫患者有许多治疗优势。它具有良好的药代动力学特征(良好的生物利用度、线性药代动力学、蛋白结合不明显、缺乏肝脏代谢、快速达到稳态浓度)和低的药物相互作用潜力。推荐的起始剂量被认为是临床有效的；因此，患者在开始使用左乙拉西坦后不久就可以对癫痫有一定的保护作用。左乙拉西坦最常见的副作用是轻微的，包括嗜睡、虚弱和头晕。临床经验和荟萃分析数据表明，左乙拉西坦耐受性良好，疗效与其他抗癫痫新药相当或略好。左乙拉西坦可能对对其他抗癫痫药物无效的患者、接受药物相互作用潜力增加的药物的患者或肝功能受损的患者特别有用。
Levetiracetam is a new antiepileptic drug, structurally and mechanistically dissimilar to other marketed antiepileptic drugs. It is effective in reducing partial seizures in patients with epilepsy, both as adjunctive treatment and as monotherapy. Levetiracetam has many therapeutic advantages for patients with epilepsy. It has favorable pharmacokinetic characteristics (good bioavailability, linear pharmacokinetics, insignificant protein binding, lack of hepatic metabolism, and rapid achievement of steady-state concentrations) and a low potential for drug interactions. Recommended starting dosages are considered to be clinically effective; therefore, patients can have some protection from seizures soon after they begin levetiracetam. The most common adverse effects observed with levetiracetam are mild and include somnolence, asthenia, and dizziness. Clinical experience and data from meta-analyses indicate that levetiracetam is well tolerated, with efficacy comparable or slightly better than that observed with other new antiepileptic drugs. Levetiracetam may be particularly useful in patients who are unresponsive to other antiepileptic drugs, patients receiving drugs with increased potential for drug interactions, or those with hepatic impairment.